Observational Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2020; 11(12): 654-665
Published online Dec 15, 2020. doi: 10.4239/wjd.v11.i12.654
Exenatide once weekly combined with metformin reduced glycemic variability in type 2 diabetes by using flash glucose monitoring system
Yang Li, Min-Min Han, Qiong He, Zi-Ang Liu, Dong Liang, Jing-Tian Hou, Yi Zhang, Yun-Feng Liu
Yang Li, Min-Min Han, Qiong He, Dong Liang, Jing-Tian Hou, Yun-Feng Liu, Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
Zi-Ang Liu, Department of First Medical College, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
Yi Zhang, Department of Pharmacology, Basic Medical College, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
Author contributions: Liu YF and Zhang Y designed the study and revised the manuscript; Li Y and Han MM drafted the initial manuscript; Li Y, Han MM, and He Q analyzed and interpreted the data; Liu ZA, Liang D, Hou JT, Li Y, Han MM, and He Q conducted the study and collected the data. All authors read and approved the final manuscript for publication.
Supported by National Natural Science Foundation of China, No. 81770776 and No. 81973378; Cultivate Scientific Research Excellence Programs of Higher Education Institutions in Shanxi, No. 2019KJ022; and Special Project for Transformation and Guidance of Scientific and Technological Achievements in Shanxi Province, No. 201804D131044.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of the First Hospital of Shanxi Medical University.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yun-Feng Liu, PhD, Chief Physician, Professor, Department of Endocrinology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Yingze District, Taiyuan 030001, Shanxi Province, China. nectarliu@163.com
Received: June 27, 2020
Peer-review started: June 27, 2020
First decision: September 18, 2020
Revised: October 9, 2020
Accepted: October 26, 2020
Article in press: October 26, 2020
Published online: December 15, 2020
Processing time: 168 Days and 14.7 Hours
Core Tip

Core Tip: In this study, flash glucose monitoring system was used not only to observe the hypoglycemic effect of and the improvement of glycemic variability by exenatide once weekly in combination with metformin, but also to accurately assess the specific time period for the improvement of blood glucose and the time when the occurrence of hypoglycemia was concentrated. The results indicated that the combination of these drugs significantly improved fasting blood glucose, but the risk of increasing hypoglycemia, especially at night, should be cautioned.